Immuneering Corporation

NasdaqGM IMRX

Immuneering Corporation Market Capitalization on January 14, 2025: USD 60.55 M

Immuneering Corporation Market Capitalization is USD 60.55 M on January 14, 2025, a -65.82% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Immuneering Corporation 52-week high Market Capitalization is USD 207.90 M on February 20, 2024, which is 243.36% above the current Market Capitalization.
Immuneering Corporation 52-week low Market Capitalization is USD 31.98 M on August 16, 2024, which is -47.18% below the current Market Capitalization.
Immuneering Corporation average Market Capitalization for the last 52 weeks is USD 77.29 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGM: IMRX

Immuneering Corporation

CEO	Dr. Benjamin J. Zeskind M.B.A., Ph.D.
IPO Date	July 30, 2021
Location	United States
Headquarters	245 Main Street
Employees	66
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Key trends

Past 5 years